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LHONeuropathy (LHON) was the ﬁrst maternally inherited mitochondrial disease
identiﬁed and is now considered the most prevalent mitochondrial disorder. LHON patients harbor
mutations in mitochondrial DNA (mtDNA). In about 90% of cases, the genes involved encode proteins of the
respiratory chain complex I. Even though the molecular bases are known since 20 years almost all remains to
be done regarding physiopathology and therapy. In this study, we report a severe decrease of complex I
activity in cultured skin ﬁbroblasts isolated from two LHON patients harboring mutations in ND4 or ND1
genes. Most importantly, we were able to restore sustainably (a) the ability to grow on galactose, (b) the ATP
synthesis rate and (c) the complex I activity, initially impaired in these cells. Our strategy consisted of forcing
mRNAs from nuclearly-encoded ND1 and ND4 genes to localize to the mitochondrial surface. The rescue of
the respiratory chain defect observed was possible by discreet amounts of hybrid mRNAs and fusion proteins
demonstrating the efﬁciency of their mitochondrial import. Hence, we conﬁrmed here for two mitochondrial
genes located in the organelle that the optimized allotopic expression approach represents a powerful tool
that could ultimately be applied in human therapy for LHON.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionLeber's Hereditary Optic Neuropathy (LHON) is a maternally
inherited neurodegenerative disorder, recognized as the most fre-
quently occurring mitochondrial disease [1]. The pathology is due to
point mutations in the mitochondrial genome. The three most
common pathogenic mutations found in about 90% of LHON′s patients
are located in ND1 (G3460A), ND4 (G11778A) or ND6 (T14484C) genes.
They encode subunits of the respiratory chain complex I and the
mutations have the double effect of lowering ATP synthesis and
increasing oxidative stress chronically. The pathology is characterized
by selective death of retinal ganglion cells and optic nerve atrophy,
prevalently in young males leading to irreversible visual failure [2].
Since the discovery in 1988 of the deleterious nucleotide substitution
G11778A in the ND4 gene [3] and thereafter the mutations in ND1 [4]
and ND6 [5] genes, the pathogenesis of LHON remains poorly
understood. One hypothesis to explain complex I dysfunction on
LHON patients underlies on the defective mitochondrial distribution
along the optic nerve head due to the abnormal organelle recruitment+33 1 53 46 25 02.
Debrinski).
l rights reserved.and their axonal transport. This would constitute the ﬁrst step of a
vicious event cycle that further compromises cell respiration which
eventually lead to profound energy depletion, increased production of
reactive oxygen species (ROS) and neuronal cell death through
apoptosis [6,7]. Besides, perturbations of the respiratory chain function
due to LHON mutations have been very complex to evidence.
Biochemical studies in patient-derived tissues and cellular experi-
mental models have produced conﬂicting results regarding the extent
of respiratory chain dysfunction associated with the disease [8,9]. The
3460/ND1 mutation induced a severe defect of complex I activity in
mitochondria from platelets, lymphoblasts and muscle while 11778/
ND4 and 14484/ND6 mutations are noticeably less severe [10–13].
Moreover, the ND4/G11778A mutation, found in 50 to 70% of patients,
is associated to an increased resistance to rotenone [14], a classical
inhibitor of complex I. Accordingly, the electron transfer through
complex I is altered in cybrid cell lines harboring LHONmutations [15–
19]. A conformational modiﬁcation of complex I structure may lead to
an increased production of ROS [20]. Indeed, it has been shown that,
while mitochondria represent the major intracellular source of ROS,
most of the superoxide radicals are produced at complex I in brain
mitochondria [21]. Another study has demonstrated an induction of
apoptosis in LHON patients due to oxidative stress [22], possibly
associated with a decrease in antioxidant defences [23]. Finally, a
recent report suggests that in primary retinal cultures glutamate
Table 1
RT-PCR analyses
mRNA RT-PCR product length (pb) Primers RT-PCR
5′ primer (5′–3′) 3′ primer (5′–3′) Quantity (ng) Cycle numbers
Endogenous ND1 252 ATACCCATGGCCAACCTCCTACTCCTC GTTGGGTATGGGGAGGGGGGTTCATAG 50 25
Hybrid ND1 248 T3 (AATTAACCCTCACTAAAGGG) CAGTCAGCATGAGGAAGGCCATGG 300 35
Endogenous ND4 227 ATGCTAAAACTAATCGTCCCAACAATT ATAAGTGGCGTTGGCTTGCCATGATTG 50 25
Hybrid ND4 330 T3 (AATTAACCCTCACTAAAGGG) CAGGAGAACAGGTTGTTGTTGATCTGG 300 35
Endogenous ATP6 248 ATGAACGAAAATCTGTTGCTTCATTC GAGTCCGAGGAGGTTAGTTGTGGCAAT 50 25
RT-PCRs were performed three times using two independent RNA preparations from LHON ﬁbroblasts and theirs counterparts allotopically expressing wild-type genes.
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the pathogenic process of LHON [24]. Themany unanswered questions
that remain about the disease's molecular pathogenesis hamper de-
vising appropriate therapeutic strategies. Several trials with vitamins
or idebenone (an oxygen radical scavenger) were performed, however
no evidence to date supports their use and prevention of vision loss in
patients [25]. Thus, allotopic expression (expression of mitochondrial
genes transferred to the nucleus) of some of mtDNA genes has been
tried in cybrid cells harboring deleterious mtDNA mutations as a
possible therapeutic option to cure LHON. In 2002, two laboratories
reported improvements in oxidative phosphorylation (OXPHOS)
function when allotopic expression was used as strategy in cybrid
cells harboring mutations in the mitochondrial ND4 and ATP6 genes
[26,27]. However, several attempts failed to conﬁrm these data and to
obtain a complete and long-lasting rescue of the mitochondrial defect
ex vivo [28,29]. Probably, the highly hydrophobic nature of proteins
encoded by the mitochondrial genome represents a physical impedi-
ment to mitochondrial import of the allotopically expressed proteins
[30]. This strongly limited the potentiality of allotopic expression as a
therapeutic approach for mtDNA-related diseases [25,31].
In a recent work we reported in ﬁbroblasts harboring the G11778A
ND4 mutation an incapacity to grow in galactose and a signiﬁcant
decrease in their ability to synthesize ATP ex vivo. The optimized allotopic
expression of the engineered nucleus-localized wild-type ND4 gene
rescued their inability togrowingalactoseand restoreanormal rateofATP
synthesis in vitro [32]. Our approach has consisted of maximizing the
positive effect onmitochondrial function by the sorting of theND4mRNA
to the mitochondrial surface, thus ensuring the mitochondrial transloca-
tionof the correspondingpolypeptide. The speciﬁc subcellular transportof
the hybrid mRNAwas achieved by the generation of an expression vector
in which the engineered ND4 gene was combined with the mRNA cis-
acting elements of the COX10 gene, since COX10 mRNA localizes
exclusively to the mitochondrial surface in HeLa cells [33].
In the present study, we examined human cultured skin ﬁbroblasts
from LHON patients carrying either the ND4/G11778A mutation or the
ND1/G3460Amutation and their counterparts allotopically expressing
nuclear recoded ND4 or ND1wild-type genes. Mitochondrial function
in these cells was assessed according to three criteria: growth capa-
city in galactose medium, ATP synthesis rate and complex I activity.
We observed in LHON ﬁbroblasts a severe decrease in complex I
activity, i.e. 60% and 80% for ND4 and ND1 mutations respectively.
Moreover, we demonstrated the presence of hybrid mRNAs and their
corresponding proteins in ﬁbroblasts stably expressing our vectors of
optimized allotopic expression. When the three criteria of mitochon-
drial functionwere monitored in these cells, we observed a signiﬁcant
restoration of OXPHOS function. In ﬁbroblasts bearing the ND1
mutation, the optimized allotopic expression vector led to an increase
of approximately 1.8-fold in the overall amount of ND1 protein, this
increase appeared to be sufﬁcient for salvaging OXPHOS in these cells.
Hence, our approach for the mitochondrial ND1 and ND4 genes
ensures the efﬁcient mitochondrial translocation of the corresponding
precursors. The rescue of the OXPHOS defect, without observable
deleterious consequences for cell ﬁtness, suggested that the processedpolypeptides were functional within their respective respiratory chain
complexes and, therefore, able to compensate for the endogenous
defective proteins.
2. Materials and methods
2.1. Plasmid construction
The construct directing the synthesis of the nuclear version of the ND4 gene,
namely COX10MTSND4-3′UTRCOX10 (WT-ND4), was obtained as previously described [32].
The mitochondrial ND1 sequence was purchased from Genscript Corp. (Piscataway,
NJ, USA). The ND1 ORF of 954 nucleotides (318 amino acids) was recoded for the 22
non-universal codons and optimized to achieve a high-level expression in human cells.
At the N-terminal extremity of the protein, it has been added in frame the ﬁrst 28 amino
acids of the human COX10 gene coding for its mitochondrial targeting sequence (MTS)
and 7 additional amino acids, to ensure the MTS cleavage by a mitochondrial processing
peptidase (MAASPHTLSSRLLTGCVGGSVWYLERRT). The COX10MTSND1-3′UTRCOX10 con-
struct (WT-ND1) was obtained according to the methodology previously described for
the COX10MTSND4-3′UTRCOX10 plasmid [32]. Final constructs were entirely sequenced
(Genome Express, France) to conﬁrm accuracy of the COX10 MTS-ND1 ORF and the
COX10 3′UTR sequences within the pCMV-Tag 4A vector (Stratagene, La Jolla, CA).
2.2. Cell culture and transfection
Cultured skin ﬁbroblasts were derived from forearm biopsies of a healthy subject (15-
month-old), a18-year-oldmanwhocarries theG11778Amutation in theND4gene (LHON#1)
and a 20-year-old man carrying the LHON ND1 G3460A (LHON #2). In both LHON patient's
ﬁbroblasts, the pathogenic mtDNAmutationwas found homoplasmic (all mtDNAmolecules
were mutated). Fibroblasts were grown under standard conditions in DMEM-Glucose
medium (Gibco, Invitrogen) supplemented with 12% fetal bovine serum (Gibco, Invitrogen),
Hepes (10 mM), uridine (2.25 mM), gentamicin (10 μg/ml), sodium pyruvate (2 mM) and
glutamine (2mM). About one half million LHON ﬁbroblasts (80,000 perwell) were seeded in
6-well plates (approximately 70% of conﬂuence). 24 h later they were transfected with
FuGENE 6 transfection reagent as recommended by the manufacturer (Roche Biochemicals,
Indianapolis). The selection was performed 68 h later with 0.15 mg/ml of G418 (Roche
Biochemicals, Indianapolis) added to the medium, which has been changed each other day.
11 days after the selection, approximately 100,000 cells were counted using aMalassez plate
after trypsination of the whole 6-well plates. We estimated the transfection yield of around
25% (numberof cells collected after 11days ofG418 selection as compared to the total amount
of cells initially seeded for the transfection). However this valuewoulddecrease if thenumber
of passages in culture of the recipient cells is higher than 6. After trypsination, cells were
seeded in the absence of G418 for 48 h. Thereafter stable clones were expanded for 3
additional weeks in the presence of G418. After each trypsination, 20% of the cells were
conserved (liquid nitrogen), the otherswere used formitochondrial function evaluation. 36 h
before each evaluation theG418waswithdrawn from themedium. In our experience, control
or untransfected ﬁbroblasts aswell as stably transfected cells cannot bemonitored rigorously
after their 12th–16th passage in culture.
2.3. Glucose/galactose assay
To determine cell ability to grow in galactose medium immediately after the
transfection, 1500 ﬁbroblasts from LHON #2 per well were seeded in two 24-well
plates. Transfections were performed 24 h later using either the COX10MTSND1-3′
UTRCOX10 or the pCMV-Tag 4A vectors. After 68 h, the cells were washed three times with
a DMEM medium lacking glucose. Plates were incubated in glucose (25 mM)- or
galactose (10 mM)-containing DMEM medium (Gibco, Invitrogen) supplemented with
12% fetal bovine serum (Gibco, Invitrogen), Hepes (10 mM), uridine (2.25 mM),
gentamicin (10 μg/ml), sodium pyruvate (2 mM), and glutamine (2 mM). The cells were
then cultured for 10 days in the presence of 0.15mg/ml G418. Themediumwas renewed
every 2 days. At 5 and 10 days, cells were trypsinized and counted with Malassez plates
to compare the amount of viable cells under each condition. In parallel, the ability of
control ﬁbroblasts to grow in either glucose or galactose media was assessed.
The capacity to grow in galactose medium of stably transfected cells was also
compared to control ﬁbroblasts. Fibroblasts stably transfected with either the
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glucose-containing medium lacking G418. After trypsination, 1500 of each transfected cells
and control ﬁbroblastswere seeded perwell into two 24-well plates. The next day, one of the
plates was extensively washed with a medium lacking glucose before the galactose-
containingmediumwas added. The cellswere cultured for 14 days, themediumof each plate
was changed every 2 days. The number of viable cells was determined, withMalassez plates,
after 14 days of growth in either glucose- or galactose-containing media.
2.4. Immunocytochemistry
Immunochemistry was performed using either themousemonoclonal anti-FlagM2
(Sigma, St. Louis, MO) or anti-ATP synthase α-subunit (Molecular Probes, Invitrogen)
antibodies, as previously described [32,34]. The membrane potential-dependent probe
MitoTracker Red CMXRos (MT) was obtained from Molecular Probes (Invitrogen) and
used as recommended by themanufacturer. Brieﬂy, coverslipswith approximately 2000
cells in a 24-well plate were grown for 36 h. Subsequently, the DMEM medium was
removed and prewarmed medium containing 10 nM of the dye was added to the cells.Fig. 1. Steady-state levels of endogenous and hybrid mRNAs from the ND4 and ND1 genes, a
RNAs extracted from untransfected or stably transfected ﬁbroblasts were subjected to RT-P
mRNAs as well as ATP6 mRNAs. 300 ng of each RNA preparation was electrophoresed on a fo
The amount of RNAs required for the reverse transcription, PCR conditions and speciﬁc olig
endogenous ND1 gene are shown in lines 1, 4, 7 and 10. The endogenous ND4mRNA results a
ND4; 8 and 11 for ND1. Hybrid mRNAs were never detected neither in untransfected cell R
endogenousND1,ND4 and ATP6mRNAs were comparable in all the RNA preparations. The am
WT-ND4. However, hybrid mRNAs were less abundant than their endogenous counterparts
signals of the ampliﬁed products (Table 1; lines 5 and 6; lines 11 and 12). B: Two independent
subject, LHON #1, LHON #2 patients and their counterparts allotopically expressing the w
analysis was performed using anti-ATP synthase α-subunit (ATPα), anti-Flag M2 (FLAG) an
(BenchMark Pre-stained Protein ladder, Invitrogen), the apparentmolecular weight of each p
mitomap.org/): ND1 ~33 kDa, ND4 ~53 kDa. Aweaker band was always detected with both an
correspond to the precursor form of the fusion protein (⁎). The ATPα protein had an apparen
analyses were performedwith signals obtained for three independentWestern blots inwhich
right panel compared the overall ND1 signal after normalizationwith theATPα signal. A signiﬁ
LHON #2 when compared with either control or LHON #1 ﬁbroblasts, according to the pa
expressing thewild-type ND1 gene, the ND1 antibody recognized both the endogenous and th
1.8-fold. Further, intensities of the two signals were signiﬁcantly different according to the pThey were incubated for 30 min under growing conditions. After the staining, cells
were ﬁxed in 3.7% formaldehyde for 15 min before proceeding to the labeling with
appropriate antibodies.
Fluorescence was observed using a Leica DM 5000 B Digital Microscope to evaluate
the subcellular distribution of the allotopically expressed polypeptides and their
possible colocalization with the endogenous ATP synthase α-subunit or with the
ﬂuorescent dye MitoTracker. The digital images were acquired and processed with the
MetaVue imaging system software.
2.5. RNA extraction, RT-PCR analyses
RNAs fromuntransfected and transfectedﬁbroblastswere obtained using RNeasy Protect
Mini kit (QIAGEN), 2×106 cellswere required foreachRNApreparation. RT-PCRanalyseswere
performed with the Superscript III one step RT-PCR Platinium Taq kit (Invitrogen). Table 1
shows the speciﬁc couple of primers used for each gene examined, the expected sizes of the
PCRproducts, thequantityofRNAused for reverse transcription, and thenumberofPCRcycles
performed.nd of the fusion ND4 and ND1 proteins in stably transfected LHON ﬁbroblasts. A: Total
CR analysis to reveal the relative abundance of hybrid and endogenous ND1 and ND4
rmaldehyde-agarose gel to assess the integrity of RNA preparations (upper-left panel).
onucleotides used for each gene are summarized in Table 1. Signals obtained from the
re presented in lines 3, 6, 9 and 12. Hybrid mRNA signals are shown in lines 2 and 6 for
NAs (lines 2 and 8) nor in control RNAs (unpublished data). Steady-state levels of the
ounts ofND1 and ND4 hybrid mRNAswere similar in LHON #2+WT-ND1 and LHON #1+
since 6 times more RNA and additional 10 cycles of PCR were required to detect similar
protein extracts were obtained from digitonin-permeabilized ﬁbroblasts from a control
ild-type ND4 and ND1 genes and subjected to Western blot analysis. Immunoblotting
d anti-ND1 antibodies (ND1) (left panel). As implied by the molecular weight markers
rotein bandwas not too different from their theoretical molecular weights (http://www.
ti-Flag and anti-ND1 antibodies in LHON #2+WT-ND1 cells of about ~37 kDa that could
t molecular weight of ~65 kDa as previously observed in HeLa cells [34]. Densitometric
each protein extractwas tested (Quantity One Biorad software system). Bar graphs in the
cant decrease on the relative amount of theND1proteinwas observed inﬁbroblasts from
ired Student's t-test (p=0.0078 and 0.003; n=6). In LHON #2 ﬁbroblasts allotopically
e fusion ND1 proteins since the intensity of the protein-signal increased of approximate
aired Student's t-test (p=0.0016; n=6).
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Protein extraction was essentially performed according to Nijtmans et al. [35].
Brieﬂy, one 75-cm2 ﬂask of ﬁbroblasts was trypsinized (about 2–4 millions of cells
depending of the conﬂuence) and washed twice with cold phosphate-buffered saline
(PBS). Cells were incubated 10 min on ice with cold digitonin (8 mg/ml in PBS, v/v) to
dissolve membranes. Digitonin was diluted by addition of cold PBS. Cells were spun for
5 min, at 10,000 ×g at 4 °C. The pellet was washed once more in 1 ml cold PBS. To
solubilize, the pellet was vigorously pipetted in buffer A containing 1.5 M aminocaproic
acid and 50 mM Bis–Tris/HCl, pH 7.0. Next, cells were incubated at 0 °C for 5 min by
addition of dodecylmaltoside (10% w/v). Cells were centrifuged at 20,000 ×g for 30 min
at 4 °C. Pellet was resuspended in buffer A. The protein concentrationwas estimated by
the Bradford protein assay (Sigma), with BSA as standard. After denaturation at 70 °C,
8 μg proteins were separated by SDS-PAGE, using a 4–12% polyacrylamide gel
(NuPAGE® system, Invitrogen) and transferred to a nitrocellulose membrane (GE
Heathcare). Membranes were probed with mouse monoclonal antibodies anti-Flag M2
(3.5 μg/mL) or anti-ATP synthaseα-subunit (0.5mg/mL) andwith a polyclonal anti-ND1
subunit antibody kindly provided by Dr. A. Lombes (1:800). Immunoreactive bands
were visualized with an anti-mouse or anti-rabbit antibodies coupled to horseradish
peroxidase (0.1 μg/mL) followed by ECL Plus detection (GE Heathcare).Fig. 2. Mitochondrial morphology in control ﬁbroblasts, untransfected and transfected LHON
healthy control subject were examined by indirect immunoﬂuorescence using antibody ag
MitoTracker Red CMXRos (MT) was used as a speciﬁc mitochondrial marker. The merged pan
The bar corresponds to 15 μm. B: Subcellular localization of the allotopically expressed protei
cells with COX10MTSND4-3′UTRCOX10 (LHON #1+WT ND4) or COX10MTSND1-3′UTRCOX10 (LH
antibodies against the Flag epitope (COX10MTSND-Flag) or against the ATP synthase α-subun
right panel. A signiﬁcant colocalization of both COX10-ND1Flag, COX10-ND4Flag, and ATP sy
Leica DM 5000 B Digital microscope. The bar corresponds to 15 μm.2.7. Biochemical assays
Rotenone-sensitive complex I, oligomycin-sensitive complex V activities and ATP
synthesis rate were assayed as recently described [32,36]. Antimycin-sensitive quinol
cytochrome c reductase (complex III activity) was measured as previously described
[37]. The quinone derivative used to measure complex III was decylubiquinol [37].
Complex IV activity is triggered by the addition of reduced cytochrome c [36]. Note that
when half the cytochrome c has been oxidized, the rate of cytochrome c oxidation is
reduced by about half. Measurement of the three respiratory chain complexes was
achieved from a single culture of skin ﬁbroblasts from patients and the control subject
and repeated for at least 12 times. Stably transfected ﬁbroblasts have been monitored
several times (4–12) using two independent stably transfected cells per patient. Each
assay was performed with 2×105 cells. Protein concentration was measured with the
Bradford assay. All chemicals were of the highest grade from Sigma (St. Louis, MO).
2.8. Statistics
Differences between control ﬁbroblasts, untransfected and transfected LHON
ﬁbroblasts were assessed using the paired Student's t-test with a minimal signiﬁcance
of pb0.05.ﬁbroblasts. A: Mitochondrial shape in ﬁbroblasts from two LHON patients and from a
ainst the ATP synthase α-subunit (ATPα). The membrane potential-dependent probe
el showed a signiﬁcant colocalization between ATP synthase α signal and MT staining.
ns and the endogenous ATP synthaseα-subunit protein ex vivo. Stably transfected LHON
ON #2+WT-ND1) plasmids were visualized by indirect immunoﬂuorescence using
it. A merged image of immunoﬂuorescence revealed with each antibody is shown in the
nthase α signals was observed in the cells examined. Fluorescence was inspected with a
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3.1. Steady-state levels of endogenous and hybrid mRNAs from the ND4
and ND1 genes, and of the fusion ND4 and ND1 proteins in stably
transfected LHON ﬁbroblasts
To estimate the efﬁciency of our constructions on directing the
expression of nuclearly-encoded ND4 and ND1 genes, we analyzed in
transfected cells the amount of hybrid mRNAs and compared it to
endogenous ND4 and ND1mRNAs by RT-PCR (Fig. 1A). The integrity of
each RNA preparation was assessed by electrophoresis; no difference
in 28S and 18S ribosomal RNA bands from the different RNA samples
examined was observed conﬁrming the integrity of the preparations
(Fig. 1A upper-left panel). Moreover, the amount of the endogenous
mitochondrial ATP6 mRNA was similar in transfected and untrans-
fected LHON ﬁbroblasts (Fig. 1A, upper-right panel). Hybrid mRNAs
produced from both COX10MTSND4-3′UTRCOX10 and COX10MTSND1-3′
UTRCOX10 vectors were only detected in LHON #1+WT ND4 and LHON
#2+WT ND1 ﬁbroblasts respectively (Fig. 1A, bottom panel). Despite
the strength of the CMV promoter, these cells did not accumulate very
high levels of hybridND4 andND1mRNAs as compared to endogenous
mRNAs. Indeed as shown in Table 1, 35 cycles of ampliﬁcation and
300 ng of RNA extraction were required to obtain an amount of PCR
product for hybrid mRNAs comparable to the one detected from the
endogenous mRNAs, which only needed 50 ng of RNAs and 25 cycles
of ampliﬁcation.
To determinewhether hybridmRNAswere translated in detectable
levels of fusionwild-type ND4 and ND1 proteins, protein extracts from
digitonin-permeabilized ﬁbroblasts were subjected to Western-blot-
ting analyses. Immunoblots were ﬁrst performed using anti-ATPFig. 3. A ﬁbroblast' ability to grow in galactose selective medium. A: After 10 days of grow
transfected with either the pCMV-Tag 4A vector or with the COX10MTSND1-3′UTRCOX10 plasm
20 μm). Cells allotopically expressing the wild-type version of ND1 exhibited a substantia
transfected LHON #2 ﬁbroblasts. B: Cell survival after 5 or 10 days of galactose selection m
ﬁbroblasts transfectedwith the COX10MTSND1-3′UTRCOX10 plasmid (2). The two transfected ﬁb
graphs represented the cell growth capacity in galactose compared to that in glucose. One hu
tested cells. Experiments were performed six times, Student's t-test established that th
(COX10MTSND1-3′UTRCOX10) compared to mock-transfected cells (pb0.0001, n=6).synthaseα antibody. This naturally importedmitochondrial protein of
respiratory complex V was present, as a single band of approximately
65 kDa, in similar amount in all cells tested (Fig. 1B). The anti-Flag
antibody was used to detect the fusion proteins, since a ﬂag epitope
was appended in frame to the C-terminus of each protein. The
antibody revealed one band of approximate 53 kDa in ﬁbroblasts
transfected with the COX10MTSND4-3′UTRCOX10 vector (LHON #1+WT-
ND4), and two forms of about 37 (⁎) and 33 kDa in cells expressing the
COX10MTSND1-3′UTRCOX10 gene (LHON #2+WT-ND1), as implied by
the molecular weight markers. The larger band could represent the
precursor form of the fusion ND1 protein; indeed its signal was always
weaker as compared to the one detected for the form of about 33 kDa.
Both ND4 and ND1 fusion proteins detected by the anti-Flag antibody
presented electrophoretical properties similar to the ones expected
from their theoretical molecular weights of approximate 51.69 kDa
and 35.66 kDa respectively (http://www.mitomap.org/). No signal was
detected with the anti-Flag antibody in the other samples examined.
The amount of ND1 protein was compared in each protein extract
using a polyclonal anti-ND1 subunit antibody (Fig. 1B). Noticeably, the
amount of the endogenous ND1 proteinwas low in ﬁbroblasts bearing
the 3460/ND1 mutation. After normalization with the amount of ATP
synthaseα, a 2.7 or 2.1-fold reduction in the amount of ND1 protein in
these cells was observed when compared to control ﬁbroblasts and
ﬁbroblasts harboring the 11778/ND4 mutation respectively. In ﬁbro-
blasts expressing the COX10MTSND1-3′UTRCOX10 gene (LHON #2+WT-
ND1), the anti-ND1 antibody was able to recognize both the en-
dogenous and the fusion protein. Indeed the difference between these
ﬁbroblasts and controls or ﬁbroblasts harboring the 11778/ND4
mutation was of only 1.46 and 1.3-fold respectively (Fig. 1B, right
panel). Additionally, the anti-ND1 antibody detected a slightly largerth in galactose medium, LHON #2 untransfected ﬁbroblasts and LHON #2 ﬁbroblasts
id (LHON #2+WT-ND1) were observed by photonic microscope (10×, the bar represent
l increase in growth rate in galactose medium compared to untransfected and mock-
easured in LHON #2 cells transfected with the pCMV-Tag 4A vector (1) and LHON #2
roblasts were compared to control ﬁbroblasts (C) after 10 days of galactose selection. Bar
ndred percent represents the total number of cells that grew in glucose medium for each
e abilities to grow in galactose were signiﬁcantly improved in the transfected cells
Table 2
Ability of LHON ﬁbroblasts carrying the ND1 mutation and their counterparts
expressing the recoded ND1 gene to grow in galactose medium
Number of cells/ml
(glucose)
Number of cells/ml
(galactose)
Survival rate %
(galactose/glucose)
LHON #2+
pCMV-Tag 4A
31250±957 4300±600 13,76
Control 31075±4728 28500±4102 91.7
LHON #2+
WT-ND1
34325±4261 23950±3879 69.8
The viability of stably transfected cells with either the pCMV-Tag 4A vector (LHON#2+pCMV-
Tag 4A) or the COX10MTSND1-3′UTRCOX10 vector (LHON #2+WT-ND1) was measured after
14 days of growth in either glucose- or galactose-containing media and compared to control
ﬁbroblasts. Four independent experiments were performed and the amount of viable cells
under each conditionwas obtained by counting with Malassez plates. The overall number of
viable cells in galactose medium was signiﬁcantly different according to the Student's t-test
when LHON #2+WT-ND1 and LHON #2+pCMV-Tag 4 ﬁbroblasts were compared (p=0.0016,
n=4) as well as for LHON #2+pCMV-Tag 4 versus control ﬁbroblasts (p=0.0014, n=4). In
contrast, no signiﬁcant difference was evidenced in the total number of cells after 14 days of
growth in galactose between LHON #2+WT-ND1 and control ﬁbroblasts (p=0.28, n=4).
Table 3
Measurement of mitochondrial ATP synthesis in digitonin-permeabilized ﬁbroblasts
μM ATP/min/106 cells/mg protein
Pyruvate/malate
Control 2423.1±125.7
LHON #2 605.5±72.8
LHON+pCMV-tag 4A 730.4±76.5
LHON+WT-ND1 1979.0±168.8
The rate of ATP synthesis, expressed in μMATP/min/106 cells/mg protein, was measured
after 5 days of growth in glucose medium, in control ﬁbroblasts, LHON #2 ﬁbroblasts,
LHON #2 ﬁbroblasts stably transfected with the pCMV-tag 4A vector and LHON #2
ﬁbroblasts stably transfected with COX10MTSND1-3′UTRCOX10 plasmid (LHON #2+WT-
ND1). Three independent experiments were performed using pyruvate/malate
(complex I-linked substrates). No signiﬁcant difference in the ATP synthesis capacity
was observed between control cells and ﬁbroblasts allotopically expressing ND1 for
complex I-linked substrates, conﬁrming the rescue of the respiratory chain defect.
ATP, adenosine triphosphate; LHON, Leber's Hereditary Optic Neuropathy.
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correspond to the precursor form of the fusion ND1 protein (Fig. 1B,
bottompanel ⁎). These results indicate that optimized allotopic expression
led to the production of detectable amounts of the fusion ND4 and ND1
proteins. Interestingly in LHON #2 ﬁbroblasts, we observed that both the
endogenous ND1 gene and the one synthesized from our vector directed
the synthesis of similar amounts of proteins. The question arises whether
the fusion ND4 and ND1 proteins localize to mitochondria and can com-
pensate the defective endogenous protein in these cells.
3.2. Mitochondrial subcellular distribution of allotopic ND1 and ND4
gene products in human ﬁbroblasts
First, we examined the mitochondrial morphology in ﬁbroblasts
from two patients harboring the G11778A ND4 (LHON #1) and
G3460A ND1 (LHON #2) substitutions. We used the membrane
potential-dependent probe MitoTracker Red CMXRos as a mitochon-
drial marker as well as a monoclonal antibody directed against the α-
subunit of mitochondrial ATP synthase. The two labelings are perfectly
superimposable (see Fig. 2A, merged panel). In about 90% of LHON #1
ﬁbroblasts, both the anti-ATP synthase α-subunit monoclonal anti-
body and the MitoTracker probe revealed a punctuate distribution of
ﬂuorescent dots, as recently described [32] (Fig. 2A). This mitochon-
drial fragmented appearance may indicate a perturbation in the
balance between the organelle fusion and ﬁssion in these cells. The
remaining cells showed long and tiny ﬁlaments around the nuclear
envelop. By contrast, in 90% of LHON #2 ﬁbroblasts, mitochondria
appeared more elongated and with a shape more complex than in
LHON #1 ﬁbroblasts (Fig. 2A). The mitochondrial morphology in the
two patient ﬁbroblasts was undeniably different. Additionally, in
ﬁbroblasts from a healthy subject (Fig. 2A, Control) less than 5% cells
showed a fragmented mitochondrial morphology. Thus, control
ﬁbroblasts and ﬁbroblasts from the LHON #2 patient displayed a
similar mitochondrial morphology. This observation suggests that in
ﬁbroblasts examined the ND4 mutation reduced mitochondrial shape
complexity at a higher extent than the ND1 mutation.
Fibroblasts from the two patients were subsequently stably trans-
fected with constructions leading to the expression of engineered
nucleus-localized wild-type ND4 or ND1 genes, respectively. To in-
crease the probability for the hydrophobicND1orND4precursors to be
efﬁciently translocated inside mitochondria, we combined to the ND4
and ND1 ORFs the sequence encoding the MTS and the 3′UTR from the
COX10 gene, as we recently reported [32]. Then, we examined by
indirect immunoﬂuorescence the ability of the proteins synthesized
from these plasmids to localize to mitochondria using the anti-Flag
antibody. There was a colocalization of the anti-Flag and the ATPsynthase α-subunit antibodies for each transfected ﬁbroblasts exam-
ined (Fig. 2B). The overlay of the two speciﬁc antibody labelings
indicates that allotopically expressed proteins and the endogenous
mitochondrial ATP synthase α-protein were distributed in the same
subcellular compartment in vivo. Moreover, in ﬁbroblasts allotopically
expressing the COX10MTSND4-3′UTRCOX10 vector (Fig. 2B, LHON #1+
WT-ND4) we consistently observed a less dotted appearance of their
mitochondria as compared to untransfected ﬁbroblasts (Fig. 2A) or
ﬁbroblasts transfected with the pCMV-Tag 4A vector (unpublished
data). Mitochondria appeared more elongated and networks were
visualized in approximately 40% of cells, indicating that themitochon-
drial shape in LHON #1 after transfection becamemore comparable to
the one observed in both control and LHON #2 ﬁbroblasts. Thus, the
optimized allotopic expression of the wild-type ND4 and ND1 genes in
ﬁbroblasts carrying these genes mutated led to the accumulation of
fusion proteins in the mitochondrial compartment.
3.3. The ability to grow in galactose medium is improved in LHON
ﬁbroblasts carrying the G3460A substitution by the allotopic expression
of ND1 gene
It has beenwell documented that when galactose replaces glucose
as the carbon source in the medium, cells deﬁcient in mitochondrial
function are greatly curtailed in their growth rate [15,38]. We have
recently described a 3.5-fold decrease in the growth rate of LHON #1
ﬁbroblasts compared to control cells after 8 days of growth in galactose
medium. This decrease was compensated when LHON #1 ﬁbroblasts
allotopically expressed the COX10MTSND4-3′UTRCOX10 vector [32]. To
determine whether LHON #2 ﬁbroblasts presented also a curtailed
growth rate in galactose and to evaluate the impact of ND1 allotopic
expression, the overall number of cells transfected with either the
pCMV-Tag 4A or the COX10MTSND1-3′UTRCOX10 vectors was estimated
after 5 or 10 days of culture in either glucose or galactose media;
immediately after transfection. Fig. 3A shows a striking negative
impact on cell survival after 10 days of culture in galactose medium in
untransfected LHON #2 cells and their counterparts transfected with
the pCMV-Tag 4A plasmid as compared to ﬁbroblasts allotopically
expressing the wild-type gene. Fibroblasts from a healthy subject did
not showdifferences in their growth rates when glucose- or galactose-
containing medium were measured. Indeed, after 10 days of growth
in galactose the overall amount of cells was 92.96%±8.4 compared
to the cells grown in glucose (Fig. 3A; p=0.20, n=6). We observed an
approximately 7-fold decrease in the growth rate of LHON #2
ﬁbroblasts transfected with the pCMV-Tag 4A compared to control
cells after 10 days of growth in galactose medium (Fig. 3B). LHON #2
ﬁbroblasts expressing the COX10MTSND1-3′UTRCOX10 vector (LHON#2+
WT-ND1) showed a 5.1- and a 5.9-fold improvement (pb0.0001, n=6)
after 5 and 10 days in their ability to grow in galactose compared to
Fig. 4. Restoration of complex I activity in LHON-transfected ﬁbroblasts. A: Illustrative curve for the successive measurement of rotenone-sensitive complex I and oligomycin-
sensitive complex V activities. B: Typical curve for the measurement of cytochrome c activity. C: Enzymatic activity measurement of rotenone-sensitive complex I and oligomycin-
sensitive complex V activities for control ﬁbroblasts (a), LHON #1 (b), LHON #1+WT-ND4 (c), LHON #2 (d) LHON #2+WT-ND1 (e) and NARP+WT-ATP6 (f). ATP, adenosine
triphosphate; cyt, cytochrome; DQ, duroquinone (oxidized); KCN, potassium cyanide; LDH, lactate dehydrogenase; MgCl2, magnesium chloride; NADH, reduced nicotinamide
adenine dinucleotide; oligo, oligomycin; PEP, phosphoenol pyruvate; PK, pyruvate kinase; red, reduced. Numbers along the traces corresponds to activity expressed as nmol/min/mg
protein. D: Table shows the enzyme activities ratio (IV/I), (V/I) and (III/IV) for control ﬁbroblasts (Control), untransfected LHON cells (LHON #1 and LHON #2), LHON ﬁbroblasts
allotopically expressing ND1 or ND4 (LHON #1+WT-ND4 and LHON #2+WT-ND1) and NARP cells allotopically expressing ATP6 used as control (NARP+WT-ATP6). The number of
experiments was indicated in brackets. The difference between LHON #1 and LHON #1+WT-ND4 was statistically signiﬁcant (pb0.0001, n=12 for IV/I; pb0.0001, n=9 for V/I). For
LHON #2, the ratio of V/I activity was also signiﬁcantly different when the couple LHON #2 and LHON #2+WT-ND1 was compared (p=0.0005, n=3). No signiﬁcant difference was
observed between control and LHON ﬁbroblasts in the enzyme activity ratio (III/IV): p=0.45 and 0.61, n=5 for LHON #1 and LHON #2 respectively).
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(Fig. 3B).
To further evaluate the impact of ND1 allotopic expression on the
growth rate in galactose medium the number of stably transfected
cells with either the pCMV-Tag 4A or the COX10MTSND1-3′UTRCOX10
vectors were evaluated after 14 days of growth in either glucose or
galactosemedia and compared to the overall number of viable cells for
control ﬁbroblasts under the same conditions (Table 2). The survival
rate on galactose medium was improved of about 5.1 fold (p=0.0016,
n=4) in cells expressing the recoded ND1 gene, strengthening the data
obtained immediately after transfection. Moreover, cell growth rates
in galactose were not statistically different between control cells
and ﬁbroblasts allotopically expressing the ND1 gene after 14 days of
selection (p=0.28, n=4).
Thus, as we have recently reported for cells carrying the ND4
G11778A substitution [32], the allotopic expression of the engineered
nucleus-localized ND1 gene led to a signiﬁcant beneﬁt for mitochon-
drial function measured by the ability to growth in galactose of cells
harboring the G3460A substitution.
3.4. Decrease of ATP synthesis in LHON #2 ﬁbroblasts was rescued by the
allotopic expression of ND1
The impairment of energy metabolism due to mutations in mtDNA
encoded genes has been frequently correlatedwith a reduced ability of
cells harboring these mutations to synthesize ATP in vitro from ADP
and Pi through the action of respiratory chain complex V [39]. There-
fore, to further conﬁrm that allotopically expressed ND1 gene product
was functional within complex I, oligomycin-sensitive ATP production
by digitonin-permeabilized ﬁbroblastswasmeasured using complex I-
linked (malate/pyruvate) substrates (Table 3). For LHON#2 ﬁbroblasts,
we evidenced a 75% reduction in the rate of complex I-dependent ATP
synthesis when compared to controls (p=0.0004, n=3). When LHON
#2 ﬁbroblasts were transfected with the mock vector, we showed a
decrease of approximatively 70% in ATP synthesis statistically sig-
niﬁcant for complex I-linked substrates (pb0.0001, n=3 for pyruvate/
malate). ATP synthesis measurement in LHON ﬁbroblasts alloto-
pically expressing the engineered ND1 gene (LHON #2+WT-ND1)
indicated an almost complete recovery in the rate of complex I-
dependent ATP production (80% relative to control). A statistically
signiﬁcant difference was reached between LHON #2 ﬁbroblasts and
cells allotopically expressing the ND1 gene: p=0.0018, n=3 for
pyruvate/malate (Table 3). The difference between cells expressing
ND1 and mock-transfected ﬁbroblasts was also signiﬁcant (p=0.003,
n=3 for pyruvate/malate). These data establish that the allotopic
expression of ND1 corrected the energy metabolism impairment of
ﬁbroblasts harboring the G3460A ND1 substitution.
3.5. The allotopic expression of ND4 or ND1 genes leads to restoration of
complex I activity in LHON ﬁbroblasts harboring these genes mutated
Since, both in vivo and in vitro biochemical studies in different
patient-derived tissues and cellular experimental models have
produced conﬂicting results regarding the extent of respiratory chain
dysfunction in LHON [8,9], we decided to perform spectrophotometric
assays [36] tomeasure the activity of respiratory complexes I, III, IV and
V in LHON ﬁbroblasts and their counterparts stably transfected with
either ND4 or ND1 genes. In these experiments, we also used NARP
ﬁbroblasts allotopically expressing ATP6 gene as an internal control of
fully respiratory chain function recovery [32] (Fig. 4). These measure-
ments allow to estimate the severity of respiratory chain defects in
these ﬁbroblasts and to further validate the rescue by the optimized
allotopic expression approach.We consistently observed differences in
the rotenone-sensitive complex I activity (I) between control ﬁbro-
blasts and LHON ﬁbroblasts (Fig. 4C, compare a, b and d). By contrast,
we did not observe signiﬁcant differences between control, LHON #2+WT-ND1, LHON #1+WT-ND4 and NARP+WT-ATP6 kinetics (Fig. 4C,
compare a, c, e and f). No signiﬁcant difference was observed in the III/
IV ratio between control, LHON #1 and LHON #2 ﬁbroblasts (Fig. 4D).
When the two enzymatic activity ratios (IV/I) and (V/I) were assessed,
we noticed an increase in the two ratios in LHON ﬁbroblast cells,
indicating that they presented a marked defect in complex I activity.
Indeed, we observed a 1.7- and 2.4-fold increase (pb0.0001) of LHON
#1 ﬁbroblasts and a 2.6- and 4-fold of LHON #2 ﬁbroblasts in the IV/I
and V/I ratios, respectively (Fig. 4D). Interestingly, ﬁbroblasts alloto-
pically expressing ND4 and control ﬁbroblasts revealed almost
identical IV/I and V/I activity ratios. A statistical differencewas reached
between LHON #1 untransfected ﬁbroblasts and their counterparts
allotopically expressing the ND4 gene (pb0.0001, n=12 for the IV/I
ratio and pb0.0001, n=12 for the V/I ratio) (Fig. 4D). In LHON
ﬁbroblasts expressing the engineered ND1 gene, we obtained a partial
restoration of the complex I activity (60% for the V/I ratio). The
difference between LHON #2 ﬁbroblasts and cells expressing ND1was
signiﬁcant for this ratio (p=0.0005, n=3). Hence, the spectrometrically
performed assay of complex I enzymatic activity in LHON ﬁbroblasts
harboring either the ND4 or the ND1 mutations was effective in the
detection of a severe defect on these cells as compared to controls.
Moreover, the measurements of complex III, IV and V activities clearly
demonstrated that OXPHOS defect in these ﬁbroblasts is restricted to
complex I. Since a signiﬁcant improvement of its activity was
consistently noticed in stably transfected cells, the fusion ND4 and
ND1 proteins synthesized from our vectors appear to be functional
within the respiratory chain complex I and able to compensate for the
endogenous defective gene products.
4. Discussion
Mitochondrial disorders can not be ignored anymore in most
medical areas. They include speciﬁc and widespread organ involve-
ment, with tissue degeneration or tumor formation. Primary or
secondary actors, mitochondrial dysfunctions are also playing a role
in the ageing process [40,41]. Research dealing with mitochondrial
physiology and pathology has almost 20 years of history all over the
world. Despite the progresses made in the identiﬁcation of disease
molecular bases, nearly all remains to be done regarding therapy [25].
The Leber's Hereditary Optic Neuropathy (LHON), a mitochondrial
genetic disease, represents the main cause of male adolescent
blindness. Its prevalence has been estimated at ∼1 over 25,000 in
the north east of England. Few data exist on the absolute prevalence of
LHON for other populations, except in Australia where 2% of people on
the blind register suffer from LHON [42]. Unfortunately since
pathogenic mechanisms of LHON are not yet understood there are
no efﬁcient therapies for its treatment. Quantiﬁcations of complex I
activity were controversial in cybrids which were used as cellular
models to evaluate mitochondrial complex I defects in patients
harboring LHON mutations [15,19]. Cybrid cells are valuable in
mitochondrial research to better understand mechanisms of several
pathologies with mitochondrial implications, but they remain an
“artiﬁcial” system contrary to ﬁbroblasts which are supposed to
reproduce more accurately natural physiological responses. Addition-
ally studies performed with muscle tissues or lymphocytes led also to
contentious results. For example, Majander et al. did not observe any
decrease in complex I activity in lymphoblasts harboring the ND4
mutation [11] whereas Larsson et al. observed a 50% reduction [10].
Nonetheless, it has beenwell established that LHON patients with the
ND1mutation are more affected than patients with the ND4mutation.
Compilation of experimental data showed a 60 to 80% decrease in
complex I activity in cells harboring the ND1mutationwhereas only a
0 to 50% reductionwas detected in cells bearing theND4mutation [42].
Up until today, we were able to ﬁnd only one report on LHON
ﬁbroblasts OXPHOS studies ex vivo. Cock et al. have reported an
approximate 60% defect in mitochondrial NADH CoQ1 reductase
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However, complex I-linked ATP synthesis rate was normal in these
ﬁbroblasts [13]. We reported here using spectrophotometric measure-
ments that skin ﬁbroblasts carrying the ND1 (LHON #2) and ND4
(LHON #1) mutations presented consistent 80% and 60% decreases in
complex I activity respectively. This is probably due to the high
sensitivity and robustness of the spectrometric assay performed [36].
Indeed, the sequential determination of complex activities on the same
sample allows the determination of enzyme activity ratios. This latter
parameter has been previously shown to be the most efﬁcient for
detecting isolated and partial impairment of respiratory chain activity
[43].
Notably, the cellular morphology of mitochondria in LHON #1
ﬁbroblasts always showed punctuate dots suggesting an enhanced
organelle ﬁssion in these cells in contrast to the LHON #2 ﬁbro-
blasts or control ﬁbroblasts which revealed more elongated and more
branched mitochondria. Recently, Koopman et al. evidenced a re-
lationship between complex I deﬁciency in ﬁbroblasts obtained from
patients carrying mutations in nuclear genes encoding complex I
subunits and the mitochondrial shape. These authors claimed that
changes in mitochondrial morphology (“mitochondrial complexity”)
are directly dependent on the severity of complex I deﬁciency. They
distinguished two categories of ﬁbroblasts: one presenting fragmen-
ted mitochondria, severe complex I amount and activity defects. The
second group displayed a normal mitochondrial appearance and
moderate complex I defects [44]. From our observations, LHON #1
ﬁbroblasts would be categorized in the “fragmented mitochondria”
group while LHON #2 cells would belong to the “normal appearance”
group. However, the morphology difference does not correlate with
the severity of complex I deﬁciency extent, since LHON #2 cells with
normal mitochondrial appearance presented the more severe com-
plex I defect. Alternative explanations should therefore be envisaged.
For example, differential effects on morphology might be associated
with differences in the role of ND1 and ND4 in complex I assembly,
and thus in mitochondrial organization [45,46]. There is also a
possibility that “mitochondrial complexity” could be more dependent
on nuclear genes encodingmitochondrial proteins as described for the
OPA1 gene product involved in Dominant Optic Atrophy [7]. Interest-
ingly, upon allotopic expression of ND4 gene LHON #1 ﬁbroblasts, the
overall mitochondrial morphology became similar to the “normal”
class and to both control and LHON #2 ﬁbroblasts (Fig. 2B).
In a previous study, we measured two independent parameters of
mitochondrial function in LHON ﬁbroblasts harboring the ND4
mutation (LHON #1) and their counterparts allotopically expressing
the wild-type gene: (i) cells' ability to grow in a galactose-containing
medium that relies on oxidative phosphorylation and (ii) cells'
capacity to produce ATP in vitro. According to these two criteria, we
have demonstrated that optimized allotopic expression of the wild-
type ND4 gene allowed a long-lasting beneﬁt for mitochondrial
function in these cultured ﬁbroblasts harboring the ND4 mutation
[32]. In the present study, we established unequivocally the complete
restoration of OXPHOS function in these ﬁbroblasts by measuring
complex I, IV and V activities. Indeed, by analyzing two independent
stably transfected ﬁbroblasts with the COX10MTSND4-3′UTRCOX10
vector, no signiﬁcant difference was detected between these trans-
fected cells and controls regarding complex I enzymatic activity. The
increased number of experiments, compared to our previous work
[32] allowed to statistically conﬁrm the restoration of complex I
activity in stably transfected cells (V/I ratios of 1.66±0.49 and 1.35±
0.50 in patient cells and controls respectively, Fig. 4). Subsequently,
our goal was to alleviate mitochondrial dysfunction in ﬁbroblasts
carrying the G3460A mutation (LHON #2) using ND1 optimized
allotopic expression. These engineered ﬁbroblasts retained a long-
term expression of the ND1 gene and were able to survive for up to
14 days in a medium inwhich glucose had been replaced by galactose.
To further validate that our approach conferred a real improvement ofmitochondrial function in LHON #2 ﬁbroblasts we measured the
actual mitochondrial ATP synthesis capacity of cells allotopically
expressing the wild-type gene. Stably transfected cells displayed a
signiﬁcantly improved ATP synthesis rate when complex I substrates
were used. The overall ATP production rate of these cells became 80%
relative to controls (Table 3). Since we were aware that increased ATP
synthesis cannot be viewed as unequivocal evidence of rescue of
mitochondrial dysfunction we spectrometrically assessed complex I
enzymatic activity in untransfected and transfected LHON #2
ﬁbroblasts as we did for LHON #1 cells. For LHON #2 ﬁbroblasts, our
optimized allotopic approach led to a partial but signiﬁcant rescue of
complex I defect. The amount determination of the ND1 protein
presenting the deleterious substitution of an alanine by a threonine at
codon 52 (A52T) in patient's ﬁbroblasts showed that there was a clear
diminution of about 2.7-fold when compared to normal ﬁbroblasts.
This striking diminution can explainwhy the inactivation of complex I
is more pronounced in LHON #2 (ND1/3460) than in LHON #1 (ND4/
11778) ﬁbroblasts (80% vs. 60%). Moreover, it is considered that ND1
plays a central role in the ﬁrst step of complex I biogenesis. ND1 is
found in a separate, smaller complex before its association with other
ND subunits [45,46]. Since LHON #2 ﬁbroblasts accumulated
signiﬁcant lesser amount of ND1 than control cells, this might be
more detrimental to the functional assembling of complex I than the
ND4 mutation. When LHON #2 ﬁbroblasts allotopically expressed
the wild-type gene, an unambiguous 1.85-fold increase in the overall
amount of ND1 proteins was evidenced resulting in a partial but
signiﬁcant restoration of complex I activity. Thus, we believe that the
protein synthesized from our vector is directly responsible of complex
I activity restoration. Twomechanisms can be envisaged: (1) the A52T
substitution is detrimental for the endogenous protein that could
become instable and unable to be recruited in themultimeric complex
I. In this case the fusion protein can take its place during its biogenesis
(2) conversely, even instable at least some ND1 molecules could be
incorporated in complex I and in cells expressing our vector, the fusion
protein, expressed at comparable levels, is able to replace the
defective one within the complex and thus rescuing partially the
complex I defect.
Finally, we havemeasured the IV/I and III/IV complex activity ratios
in both LHON ﬁbroblasts to determine whether complex I defect in
these cells is associated to either complex IV or complex III decreased
activities. Both complex activities were similar in these cells to that of
controls and conﬁrmed that they presented an isolated complex I
deﬁciency which was signiﬁcantly alleviated by using the optimized
allotopic expression approach. Hence, our approach has led to the
accumulation of sufﬁcient amounts of functional proteins synthesized
from our vectors (Fig. 1) which created a situation very similar to the
heteroplasmy found in some patients suffering from mtDNA-related
diseases (coexistence of both wild-type and mutated mtDNA
molecules). The heteroplasmy achieved at the protein level by the
optimized allotopic expression approach drives to the restoration of
complex I activity and the improvement of the overall mitochondrial
function in these cells.
4.1. Concluding remarks
In conclusion, we are as involved as many other laboratories
worldwide in the challenge to ﬁnd ways for ﬁghting mitochondrial
diseases. However, our main limitation is the absence of animal and
cellular models required for both the understanding of the molecular
mechanisms underlying the diseases and to evaluate therapeutic
strategies, especially for mtDNA mutations. Last year, Qi et al. showed
that the nuclear version of the mutant ND4 subunit of complex I
is translocated into the mitochondria of mouse retinal ganglion
cells and led to retinal and optic nerve degeneration. This important
data represents a ﬁrst step for the generation of a murine model
resembling LHON [47]. Nevertheless, their approach encounters the
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the corresponding mRNA cannot be sorted to the mitochondrial
surface. Hence, we suspect that it is not a robust mouse model to
evaluate putative treatments. Besides, their strategy has the potential
to become toxic for mouse retina over time, indeed high levels of
misfolded hydrophobic proteins in the cytosol have been shown to be
deleterious ex vivo [29].
The data presented here and our previous work deﬁnitely con-
ﬁrmed for three mitochondrial genes (ATP6, ND4 and ND1) that the
optimized allotopic approach based on the mRNA sorting to the
mitochondrial surface is a suitable way for rescuing mitochondrial
deﬁciencies caused by mutations in mtDNA genes. Our next challenge
is to create an animal model resembling LHON and its cure using our
optimized allotopic expression approach that will open the door to
gene therapy for LHON (Ellouze et al., submitted).
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